GLP-1 receptor

Feb 03, 2025

The recent approval of OZEMPIC reinforces the growing trend of GLP-1 drugs being used for conditions beyond diabetes and weight loss. Novo Nordisk’s blockbuster GLP-1 medication, OZEMPIC, has secured another label expansion, as the FDA has now approved it for treating chronic kidney disease. The approval for chr...

Jan 06, 2025

Eli Lilly’s blockbuster weight loss GLP-1 drug ZEPBOUND has received FDA approval to treat obstructive sleep apnea in adults with obesity, alongside diet and exercise. This marks the first FDA-approved medication for obstructive sleep apnea.  The approval adds a second indication for ZEPBOUND, following its...